Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Gritstone raises $102M series A

    Gritstone Oncology Inc. (Emeryville, Calif.) raised $102 million in a series A round, the third-largest series A for a biotech this year. Versant Ventures and The Column Group led the round, which also included Clarus …

    Published on 10/20/2015
  • TOP STORY: Valeant to rely less on pricing strategy

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) CEO Michael Pearson said on the company's 3Q15 earnings call Monday that it is likely the company "will pursue fewer, if any, transactions that are focused …

    Published on 10/19/2015
  • TOP STORY: Zafgen falls on more beloranib news

    Zafgen (NASDAQ:ZFGN) plunged $10.66 (51%) to $10.36 on Friday after disclosing the Prader-Willi syndrome patient who died in the Phase III bestPWS (ZAF-311) trial was receiving the company's beloranib (ZGN-440) and not …

    Published on 10/16/2015
  • TOP STORY: BMS licenses Five Prime's CSF1R program

    Five Prime Therapeutics Inc. (NASDAQ:FPRX) jumped $11.02 (65%) to $27.93 on Thursday after it granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive, worldwide license to its colony stimulating factor 1 receptor (…

    Published on 10/15/2015
  • TOP STORY: Zafgen reports patient death

    Zafgen Inc. (NASDAQ:ZFGN) said a patient died of an unknown cause in the Phase III bestPWS trial of beloranib (ZGN-440) to treat Prader-Willi syndrome. The company said it is working with FDA to review and understand …

    Published on 10/14/2015
  • TOP STORY: Zafgen continues its fall

    Zafgen Inc. (NASDAQ:ZFGN) fell $6.40 (29%) to $15.75 on Tuesday, its second consecutive day of heavy losses. The obesity company tumbled $12.25 (36%) to $22.15 on Monday and has now lost 54% of its value, or $505.8 …

    Published on 10/13/2015
  • TOP STORY: Lilly discontinues Phase III CETP inhibitor

    Eli Lilly and Co. (NYSE:LLY) fell $6.70 to $79.44 on Monday, losing more than $7 billion in market cap after it said it will discontinue development of cholesteryl ester transfer protein (CETP) inhibitor evacetrapib (…

    Published on 10/12/2015
  • TOP STORY: Sanders critical of Califf nomination

    Sen. Bernie Sanders (I-Vt.) said he would vote against confirming Robert Califf as FDA commissioner, citing the cardiologist's industry ties. In a statement, Sanders said Americans "need a new leader at the FDA who is …

    Published on 10/9/2015
  • TOP STORY: Biopharma CEOs discuss TPP with Obama

    The Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement acknowledging Thursday's meeting between President Obama and biopharma CEOs to discuss IP protections in the Trans-Pacific Partnership.…

    Published on 10/8/2015
  • TOP STORY: Biopharma CEOs meeting with Obama on TPP

    Chairman and CEO Kenneth Frazier of Merck & Co. Inc. (NYSE:MRK), CEO George Scangos of Biogen Inc. (NASDAQ:BIIB) and other biopharma CEOs are slated to meet with President Obama on Thursday to discuss the Trans-Pacific …

    Published on 10/7/2015
  • TOP STORY: Biotech stocks down amid more bad news

    Biotech indices posted steep losses on Tuesday, wiping out most of the gains from a short rally late last week and prolonging an extended slump for the sector.Decliners outnumbered gainers by 90 to 10 among BioCentury …

    Published on 10/6/2015
  • TOP STORY: TPP provides 5-plus years of biologics exclusivity

    The Trans-Pacific Partnership trade treaty will set a floor of five years of data protection for biologics, U.S. Trade Representative Michael Froman announced Monday. Details of the agreement have not been released. …

    Published on 10/5/2015
  • TOP STORY: Amicus plummets on NDA delay

    Amicus Therapeutics Inc. (NASDAQ:FOLD) shed $7.36 (53%) to $6.39 on Friday, losing all of its 2015 gains, after the company said it no longer planned to submit an NDA to FDA by YE15 for Amigal migalastat to treat Fabry'…

    Published on 10/2/2015
  • TOP STORY: Sarepta rises on long-term Phase IIb DMD data

    Sarepta Therapeutics Inc. (NASDAQ:SRPT) jumped $7.17 (22%) to $39.28 on Thursday after reporting long-term follow-up data from Phase IIb trials of eteplirsen (AVI-4658) to treat Duchenne muscular dystrophy (DMD) …

    Published on 10/1/2015
  • TOP STORY: Biotech stocks end skid on last day of 3Q15

    Biotech indices rose Wednesday, ending an eight-day run of losses. The BioCentury 100 index gained 246.89 (4.4%) to 5,815.33. The index lost 23% during 3Q15, and is down 3.1% for the year.The NASDAQ Biotechnology Index…

    Published on 9/30/2015
  • TOP STORY: Losing streak continues for biotech stocks

    Biotech indices failed to hold intraday gains on Tuesday, losing ground for the eighth consecutive day in a sell-off that has pushed the indices into the red for the year (see BioCentury Extra, Sept. 28).The BioCentury …

    Published on 9/29/2015
  • TOP STORY: Biotech stocks give back 2015's gains

    Biotech stock indices tumbled again on Monday, and now are in the red for the year.The BioCentury 100 Index shed 405.61 (7%) to 5,671.92 on Monday. The index is down 31% since its July 20 peak of 8,161.20. For the year,…

    Published on 9/28/2015
  • TOP STORY: Biotech stocks still reeling

    Biotech stocks continued a week-long slide Friday, as indices ended the week with double-digit losses from their Sept. 18 close. The BioCentury 100 Index sank 353.51 (5.5%) to 6077.54 on Friday and finished the week …

    Published on 9/25/2015
  • TOP STORY: Novartis' NIBR taps Bradner to replace Fishman

    Novartis AG (NYSE:NVS; SIX:NOVN) named James Bradner president of the Novartis Institutes for BioMedical Research (NIBR) and a member of Novartis' executive committee.He replaces Mark Fishman, who will retire in March …

    Published on 9/24/2015
  • TOP STORY: PhRMA close to picking Ubl as CEO

    The Pharmaceutical Research and Manufacturers of America has tentatively selected Stephen Ubl as its new president and CEO, according to a board member. PhRMA spokesperson Robert Zirkelbach told BioCentury no decision …

    Published on 9/23/2015
  • TOP STORY: Biotech stocks continue down on Clinton drug plan

    Biotech stocks continued their tumble today after Hillary Clinton released her proposal to lower prescription drug costs. Biotech indices began falling yesterday in response to calls from Clinton and Sen. Bernie Sanders…

    Published on 9/22/2015
  • TOP STORY: Biotech stocks sink as Clinton, Sanders jump on Turing

    On Monday, Hillary Clinton wrote on Twitter that she will release a plan Tuesday to address "price gouging" on specialty drugs, which she called "outrageous," and referred to a New York Times story that said Turing …

    Published on 9/21/2015
  • TOP STORY: IPR tweak proposed

    Staff working for Sen. Chuck Grassley (R-Iowa), chairman of the U.S. Senate Judiciary Committee, have drafted a legislative proposal intended to address one of the drug industry's complaints about the inter partes …

    Published on 9/18/2015
  • TOP STORY: Lilly gains on Jardiance CVOT data

    Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) reported data from the EMPA-REG OUTCOME cardiovascular outcomes trial (CVOT) of Jardiance empagliflozin plus standard of care (SOC), which …

    Published on 9/17/2015
  • TOP STORY: Phase III schizophrenia data lift Intra-Cellular to record high

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI) climbed $22.68 (87%) to an all-time high close of $48.79 on Wednesday after the 60 mg dose of ITI-007 met the primary endpoint in a Phase III trial to treat schizophrenia. …

    Published on 9/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993